Supplier Woes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Supplier Woes
Production sometimes follows the law of supply and reprimand.


Pharmaceutical Technology

Unapproval confession



"It was only sheerest chance that we discovered it at all," notes our GMP-Agent-in-Place. "It was in the late 1980s when we manufactured a timed-release bead in a capsule product that was manufactured with an active ingredient from a supplier that was not in the new drug application and therefore was not approved. We had sold several batches of the product.

"Once we discovered this, the new supplier was qualified, and a supplement to the new drug application was submitted and ultimately was approved by FDA. However, the batches made with the unapproved supplier were never recalled and were left on the market!

"You can bet that we reviewed every supplier we used against the new drug applications and issued a formal list of the approved suppliers and ingredients. We also instituted a check of the supplier and ingredient list as part of the material receipt process."

Eye feel your pain



"We had produced this ophthalmic preparation for a long time, and when one adverse event for 'burning sensation' came in, we thought nothing of it," admits our GMP Agent-in-Place. "But when similar reports of adverse events came pouring in, we nearly panicked. This was a well known, well-understood formulation, and we didn't understand what could be causing these reactions.



"Finally we decided to matrix all the ingredients used in all the recent batches, whether or not there were adverse events. This process led us to determine that the common factor was a plastic resin used for making the bottles of one product. Further investigation into the matter told us that the supplier had changed the colorant in the resin without notifying us. As a result, we recalled the affected product and trashed two months of production!"

Something's fishy here

"The problem was just ordinary salt—that's right, sodium chloride," relates our GMP-Agent-in-Place. "Production volumes had increased, and our purchasing department had fallen behind in the orders for the injectable-quality salt we needed. So they had five drums air-shipped in overnight for immediate use while the main shipment was being prepared. Problem solved, right?

"Wrong.

"When the salt was received and the drums were opened for sampling, one smelled fishy. Apparently the drums had seen previous use! While the laboratory testing all passed, the smell alone was enough to reject all the drums, and another overnight air-shipment was required. They always blame the quality department, but we didn't order our ingredients to be shipped in used drums. Production was shut down for 48 hours because of the lack of salt."



Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at
. We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here